Enveric Biosciences, Inc.

ENVB

US29405E5050

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
2.100 ^USD	+3.96%		-11.39%	-42.15%

Jan. 29	Enveric Biosciences, Inc. Expands Collaboration with TOTEC Pharma Through Trademark License and Option	CI
Jan. 28	Enveric Biosciences announces closing of $1.5 million registered direct offering priced at-the-market under Nasdaq rules	RE

Enveric Biosciences receives FDA response and streamlines plans for EB-003 IND submission

Published on 09/16/2025 at 10:02 am EDT

Reuters

Latest news about Enveric Biosciences, Inc.

Jan. 29	Enveric Biosciences, Inc. Expands Collaboration with TOTEC Pharma Through Trademark License and Option	CI
Jan. 28	Enveric Biosciences announces closing of $1.5 million registered direct offering priced at-the-market under Nasdaq rules	RE
Dec. 10	Top Premarket Gainers	MT
Dec. 09	Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates	CI
Nov. 26	Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates	CI
Nov. 14	Enveric Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 14	Enveric Biosciences Q3 net loss widens	RE
25-10-23	Enveric Biosciences announces reverse stock split	RE
25-10-02	Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials	CI
25-09-29	Enveric Biosciences says selling stockholders are offering on a resale basis an aggregate of 4.8 million shares of common stock - SEC filing	RE
25-09-17	Enveric Biosciences Expects to Receive $2.2 Million From Exercise of Warrants	MT
25-09-16	Enveric Biosciences receives FDA response and streamlines plans for EB-003 IND submission	RE
25-09-16	Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission	CI
25-09-16	Enveric Biosciences to Submit Investigational New Drug Application for Depression Medication	MT
25-09-02	Enveric Biosciences Inc Relocates Corporate Headquarters to Cambridge, MA	CI

Chart Enveric Biosciences, Inc.

Duration

Period

ENVB: Dynamic Chart

Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders. The Company, through Psybrary has created a robust intellectual property (IP) portfolio of new chemical entities for specific mental health indications. Its lead program, the EVM201 Series, comprises synthetic prodrugs of the active metabolite, psilocin. It is developing the first product from the EVM201 Series, EB-002, for the treatment of psychiatric disorders. The Company is also advancing its second program, the EVM301 Series, EB 003, which is an approach to the treatment of difficult-to-address mental health disorders. Within the Psybrary, it has three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). It has created over 1,000 novel psychedelic molecular compounds and derivatives.

Employees

Sector

Biotechnology & Medical Research

Calendar

Mar. 25 - Q4 2025 Earnings Release (Projected)

More about the company